This cycle is based on CX3CL1/ICAM-1-mediated NSCLC cell-VBMEC interactions resulting in enhanced tumor cell aggressiveness and adhesion, improved VBMEC permeability, and increased NSCLC cell transendothelial migration through several signaling pathways. The gene discussed is CX3CL1; the disease is non-small cell lung carcinoma.